Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

A sequential Bayesian algorithm for dose individualisation of carboplatin

S B Duffull¹, E J Begg, B A Robinson

¹Clinical Pharmacology Department, Christchurch Hospital, New Zealand.

Cancer Chemotherapy and Pharmacology

|January 1, 1997

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Breast cancer and cytomegalovirus.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2019

Same author

Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis.

British journal of clinical pharmacology·2018

Same author

Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥7 mg Daily: A Systematic Review and Meta-analysis.

Clinical pharmacology and therapeutics·2017

Same author

A Philosophical Framework for Integrating Systems Pharmacology Models Into Pharmacometrics.

CPT: pharmacometrics & systems pharmacology·2016

Same author

A framework for quantifying the influence of adherence and dose individualization.

Clinical pharmacology and therapeutics·2016

Same author

Quantification of the Forgiveness of Drugs to Imperfect Adherence.

CPT: pharmacometrics & systems pharmacology·2015

Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026

Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026

Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026

Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026

Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026

Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026

See all related articles

This study introduces a novel Bayesian method for personalizing carboplatin chemotherapy doses. This approach optimizes treatment by targeting individual patient pharmacokinetics for improved efficacy and reduced toxicity.

Area of Science:

Pharmacology
Oncology
Biostatistics

Background:

Carboplatin offers reduced nephrotoxicity and neurotoxicity compared to cisplatin.
Myelotoxicity is the dose-limiting toxicity of carboplatin.
Individualized dosing is crucial for optimizing carboplatin's therapeutic window.

Purpose of the Study:

To develop a Bayesian dose-individualization method for carboplatin.
To create a sequential design for adjusting carboplatin doses based on serum concentrations.
To optimize carboplatin therapy by targeting individual patient pharmacokinetics.

Main Methods:

Developed a high-performance liquid chromatography (HPLC) assay for serum carboplatin measurement.
Conducted a pharmacokinetic study in 12 ovarian cancer patients.

Related Experiment Videos

Created population pharmacokinetic models and a sequential Bayesian algorithm for dose adjustment.

Main Results:

HPLC assay demonstrated high precision and a low limit of detection.
Estimated population pharmacokinetic parameters (Cl=6.8 L/h, Vss=221 L) consistent with prior studies.
A two-compartment model with specific error models effectively described carboplatin's concentration-time course.

Conclusions:

Developed the first sequential Bayesian design for carboplatin dose individualization in chemotherapy.
The developed algorithm is specific to carboplatin and operates independently of commercial software.
Prospective testing is underway to compare predicted doses against conventional methods.